» Articles » PMID: 36759819

Targeting and Regulation of Autophagy in Hepatocellular Carcinoma: Revisiting the Molecular Interactions and Mechanisms for New Therapy Approaches

Abstract

Autophagy is an evolutionarily conserved process that plays a role in regulating homeostasis under physiological conditions. However, dysregulation of autophagy is observed in the development of human diseases, especially cancer. Autophagy has reciprocal functions in cancer and may be responsible for either survival or death. Hepatocellular carcinoma (HCC) is one of the most lethal and common malignancies of the liver, and smoking, infection, and alcohol consumption can lead to its development. Genetic mutations and alterations in molecular processes can exacerbate the progression of HCC. The function of autophagy in HCC is controversial and may be both tumor suppressive and tumor promoting. Activation of autophagy may affect apoptosis in HCC and is a regulator of proliferation and glucose metabolism. Induction of autophagy may promote tumor metastasis via induction of EMT. In addition, autophagy is a regulator of stem cell formation in HCC, and pro-survival autophagy leads to cancer cell resistance to chemotherapy and radiotherapy. Targeting autophagy impairs growth and metastasis in HCC and improves tumor cell response to therapy. Of note, a large number of signaling pathways such as STAT3, Wnt, miRNAs, lncRNAs, and circRNAs regulate autophagy in HCC. Moreover, regulation of autophagy (induction or inhibition) by antitumor agents could be suggested for effective treatment of HCC. In this paper, we comprehensively review the role and mechanisms of autophagy in HCC and discuss the potential benefit of targeting this process in the treatment of the cancer. Video Abstract.

Citing Articles

Gossypol enhances ponatinib's cytotoxicity against human hepatocellular carcinoma cells by involving cell cycle arrest, p-AKT/LC3II/p62, and Bcl2/caspase-3 pathways.

Elkattan H, Elsisi A, El-Lakkany N Toxicol Rep. 2025; 14():101856.

PMID: 39802605 PMC: 11719416. DOI: 10.1016/j.toxrep.2024.101856.


Targeting the mTOR Pathway in Hepatocellular Carcinoma: The Therapeutic Potential of Natural Products.

Chen G, Zhang Y, Zhou Y, Luo H, Guan H, An B J Inflamm Res. 2024; 17:10421-10440.

PMID: 39659752 PMC: 11630751. DOI: 10.2147/JIR.S501270.


Exosomal circular RNAs in tumor microenvironment: An emphasis on signaling pathways and clinical opportunities.

Li J, Zhou W, Wang H, Huang M, Deng H MedComm (2020). 2024; 5(12):e70019.

PMID: 39584047 PMC: 11586091. DOI: 10.1002/mco2.70019.


The dual role of autophagy in suppressing and promoting hepatocellular carcinoma.

Mohammed W, Sulaiman G, Abomughaid M, Klionsky D, Abu-Alghayth M Front Cell Dev Biol. 2024; 12:1472574.

PMID: 39463763 PMC: 11502961. DOI: 10.3389/fcell.2024.1472574.


Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy.

Liu B, Liu L, Liu Y Front Immunol. 2024; 15:1450487.

PMID: 39315094 PMC: 11416969. DOI: 10.3389/fimmu.2024.1450487.


References
1.
Ashrafizadeh M, Paskeh M, Mirzaei S, Gholami M, Zarrabi A, Hashemi F . Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res. 2022; 41(1):105. PMC: 8939209. DOI: 10.1186/s13046-022-02293-6. View

2.
Chiang J . Bile acid metabolism and signaling. Compr Physiol. 2013; 3(3):1191-212. PMC: 4422175. DOI: 10.1002/cphy.c120023. View

3.
Claro S, Oshiro M, Mortara R, Paredes-Gamero E, Pereira G, Smaili S . γ-Rays-generated ROS induce apoptosis via mitochondrial and cell cycle alteration in smooth muscle cells. Int J Radiat Biol. 2014; 90(10):914-27. DOI: 10.3109/09553002.2014.911988. View

4.
Deretic V, Jiang S, Dupont N . Autophagy intersections with conventional and unconventional secretion in tissue development, remodeling and inflammation. Trends Cell Biol. 2012; 22(8):397-406. PMC: 3408825. DOI: 10.1016/j.tcb.2012.04.008. View

5.
Jing Z, Ye X, Ma X, Hu X, Yang W, Shi J . SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Cancer Med. 2020; 9(12):4324-4338. PMC: 7300419. DOI: 10.1002/cam4.3020. View